Benzylidene lactam compound KNK347, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells
Yokota S., Kitahara M., Nagata K. Benzylidene lactam compound KNK347, a novel inhibitor of acquisition of thermotolerance and heat shock protein induction in human colon carcinoma cells. Cancer Res. 60:2000;2942-2948.
Antitumor agents. Part 202: Novel 2′-amino chalcones. Design, synthesis and biological evaluation
Xia Y., Yang Z., Xia P., Bastow K.F., Nakanishi Y., Lee K. Antitumor agents. Part 202: Novel 2′-amino chalcones. Design, synthesis and biological evaluation. Bioorg. Med. Chem. Lett. 10:2000;699-701.
Structure-activity relationships of antitumor thiazolo[3,4-a]benzimidazole derivatives
Chimirri A., Grasso S., Monforte A.M., Monforte P., Zappalà M., Carotti A. Structure-activity relationships of antitumor thiazolo[3,4-a]benzimidazole derivatives. Farmaco. 49:1994;337-344.
Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines
Grasso S., Micale N., Monforte A.M., Monforte P., Zappalà M. Synthesis and in vitro antitumour activity evaluation of 1-aryl-1H,3H-thiazolo[4,3-b]quinazolines. Eur. J. Med. Chem. 35:2000;1115-1119.
A simple and efficient synthesis of GYKI 52466 and GYKI 52895
Zappalà M., Grasso S., Micale N., Polimeni S., De Micheli C. A simple and efficient synthesis of GYKI 52466 and GYKI 52895. Synth. Comm. 32:2002;527-533.
Syntheses, structure analyses, and reactions of 1,3,5-trioxepanes and related compounds
McCullough K.J., Masuyama A., Morgan K.M., Nojima M., Okada Y., Satake S., Takeda S. Syntheses, structure analyses, and reactions of 1,3,5-trioxepanes and related compounds. J. Chem. Soc., Perkin Trans. 1998;2353-2362.
Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones
Grasso S., De Sarro G., De Sarro A., Micale N., Zappalà M., Puja G., Baraldi M., De Micheli C. Synthesis and anticonvulsant activity of novel and potent 6,7-methylenedioxyphthalazin-1(2H)-ones. J. Med. Chem. 43:2000;2851-2860.
Status of the NCI preclinical antitumor drug discovery screen: Implications for selections of new agents for clinical trials
V.T. DeVita, S. Hellman, Rosemberg S.A. Philadelphia: Lippincott
Boyd M.R. Status of the NCI preclinical antitumor drug discovery screen: implications for selections of new agents for clinical trials. DeVita V.T., Hellman S., Rosemberg S.A. Cancer: Principles and Practice of Oncology Updates. 3:1989;1-12 Lippincott, Philadelphia.